287 related articles for article (PubMed ID: 30128815)
1. Prevention and Management of Bleeding Episodes in Children with Hemophilia.
Ljung RCR
Paediatr Drugs; 2018 Oct; 20(5):455-464. PubMed ID: 30128815
[TBL] [Abstract][Full Text] [Related]
2. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products.
Berntorp E; Andersson NG
Semin Thromb Hemost; 2016 Jul; 42(5):518-25. PubMed ID: 27096762
[TBL] [Abstract][Full Text] [Related]
4. Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates.
von Mackensen S; Kalnins W; Krucker J; Weiss J; Miesbach W; Albisetti M; Pabinger I; Oldenburg J
Haemophilia; 2017 Jul; 23(4):566-574. PubMed ID: 28370896
[TBL] [Abstract][Full Text] [Related]
5. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
Mahdi AJ; Obaji SG; Collins PW
Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
[TBL] [Abstract][Full Text] [Related]
6. [Congenital hemophilia: a new treatment paradigm].
Shima M
Rinsho Ketsueki; 2019; 60(6):647-658. PubMed ID: 31281158
[TBL] [Abstract][Full Text] [Related]
7. The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation.
Brennan Y; Parikh S; McRae S; Tran H
Haemophilia; 2020 May; 26(3):529-535. PubMed ID: 32243027
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia.
Morfini M; Farrugia A
Expert Rev Hematol; 2019 Oct; 12(10):883-892. PubMed ID: 31314609
[No Abstract] [Full Text] [Related]
9. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
[TBL] [Abstract][Full Text] [Related]
10. Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias.
Mancuso ME; Mannucci PM
Drug Des Devel Ther; 2014; 8():365-71. PubMed ID: 24729686
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective.
Björkman S
Haemophilia; 2003 May; 9 Suppl 1():101-8; discussion 109-10. PubMed ID: 12709045
[TBL] [Abstract][Full Text] [Related]
12. Factor Activity Assays for Monitoring Extended Half-Life FVIII and Factor IX Replacement Therapies.
Kitchen S; Tiefenbacher S; Gosselin R
Semin Thromb Hemost; 2017 Apr; 43(3):331-337. PubMed ID: 28264199
[TBL] [Abstract][Full Text] [Related]
13. New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement.
Van den Bossche D; Peerlinck K; Jacquemin M
Int J Lab Hematol; 2018 May; 40 Suppl 1():21-29. PubMed ID: 29741261
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic versus on-demand treatments for hemophilia: advantages and drawbacks.
Castaman G; Linari S
Expert Rev Hematol; 2018 Jul; 11(7):567-576. PubMed ID: 29886751
[TBL] [Abstract][Full Text] [Related]
15. Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database.
Versloot O; Iserman E; Chelle P; Germini F; Edginton AN; Schutgens REG; Iorio A; Fischer K;
J Thromb Haemost; 2021 Aug; 19(8):1896-1906. PubMed ID: 34013558
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic Treatment of Children with Hemophilia in Sweden.
Ljung R
Semin Thromb Hemost; 2024 Jul; 50(5):714-719. PubMed ID: 38499191
[TBL] [Abstract][Full Text] [Related]
17. Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management.
Müller J; Goldmann G; Marquardt N; Pötzsch B; Oldenburg J
Hamostaseologie; 2020 Nov; 40(S 01):S15-S20. PubMed ID: 33187006
[TBL] [Abstract][Full Text] [Related]
18. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.
Collins P; Chalmers E; Chowdary P; Keeling D; Mathias M; O'Donnell J; Pasi KJ; Rangarajan S; Thomas A
Haemophilia; 2016 Jul; 22(4):487-98. PubMed ID: 27311929
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in developing specific therapies for haemophilia.
Ling G; Nathwani AC; Tuddenham EGD
Br J Haematol; 2018 Apr; 181(2):161-172. PubMed ID: 29359795
[TBL] [Abstract][Full Text] [Related]
20. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
Preijers T; Bukkems L; van Spengler M; Leebeek F; Cnossen M; Mathôt R
Eur J Clin Pharmacol; 2021 Aug; 77(8):1193-1200. PubMed ID: 33624121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
